143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
11 citations
,
January 2022 in “Journal of Cancer” Low intensity ultrasound may reduce side effects of chemotherapy drugs like paclitaxel.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
5 citations
,
June 2005 in “Journal of Clinical Oncology” PPX causes much less hair loss than traditional taxanes.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
Chemotherapy for breast cancer often causes significant and lasting hair loss.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
February 2025 in “Chemico-Biological Interactions” 5-Fluorouracil causes hair loss by blocking signals needed for hair growth.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
53 citations
,
October 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
October 2025 in “Clinical Chemistry” Juniperus communis extract enhances the effectiveness of oral cancer treatment when combined with chemotherapy.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
March 2008 in “Aging health” Docetaxel is safe and works well for older people with cancer, with manageable side effects.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.